New at Biotech – Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Exelixis, Inc. (NASDAQ:EXEL), Gilead Sciences, Inc. (NASDAQ:GILD)
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) after opening at $5.74 reached its day high price of $6.44 and then closed at $5.50 by shares soared 15.55% in last trading session. A specialty pharmaceutical firm focused on developing as well as commercializing a portfolio of products for the critical care market, reported that the protocol of their phase 3 trial for levosimendan has been released on ClinicalTrials.gov, Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass.
INSIDE FACTS: As firm has the enterprise value of $48.26M. The company has the price over sales value of $73.88 whereas its price over book value of $11.36 for the most recent quarter. The firm has the total of cash of $2.54M as compares to total debt of $233.32K for the most recent quarter with the current ratio of 2.10 for the most recent quarter.
Exelixis, Inc. (NASDAQ:EXEL) surged 11.09% in last session as it has a market cap of $1.25B with outstanding shares of 184.15M. The firm was raised rating by equities research analysts at Piper Jaffray from a “neutral” rating to an “overweight” rating in a research note issued to investors on Monday.
INSIDE FACTS: As firm has the enterprise value of $1.19B. The firm has the total of cash of $279.22M as compares to total debt of $341.59M for the most recent quarter with the current ratio of 3.93 for the most recent quarter.
Gilead Sciences, Inc. (NASDAQ:GILD) performed not well, shares lost at -1.45% on volume of 8.35M shares. The stock settled at $73.24 after floating in a range of $72.73 to $74.69. The firm declared that Kevin Young CBE, Executive Vice President, Commercial Operations, has informed the firm of his decision to retire, effective February 4th. Mr. Young will maintain to work directly with Gilead’s management team as a senior advisor.
AVERAGE ANTICIPATES: For fourth quarter of 2013, the consensus average estimates of street for the revenue are 2.84B, while experts predict 3.02B revenues for the first quarter of 2014. The firm sales growth (year/est) is calculated 9.80% in Current Qtr. (Dec 13) and for first quarter 2014 was predicted -19.20%.
This content does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the company’s stocks or securities. As well nor shall there be any sale of the company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction. eMarketsdaily.com only provide news and information about stocks with intentions that it may be helpful for investor to take investment decision on their own risk. It is “RECOMMENDED” at all times do your own due diligence; along with consult your financial advisor.